Related Experiment Video
Updated: Feb 7, 2026
11:19
Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 17, 2011
18.6K
MicroRNAs for the pediatric otolaryngologist
Graham M Strub1, Jonathan A Perkins2
1Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, WA, 98105, United States; Department of Otolaryngology and Communication Enhancement, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, United States.
International Journal of Pediatric Otorhinolaryngology
|July 30, 2018
Summary
MicroRNAs (miRNAs) are key regulators of gene expression implicated in pediatric otolaryngology diseases. These molecules show promise as diagnostic biomarkers and therapeutic targets for improved patient outcomes.
Area of Science:
- Molecular Biology
- Genetics
- Pediatric Otolaryngology
Background:
- Pediatric otolaryngology involves diverse diseases rooted in gene regulation and expression abnormalities.
- Novel molecular tools are needed for accurate diagnosis, treatment monitoring, and recurrence prevention in pediatric ENT conditions.
- MicroRNAs (miRNAs) are emerging as critical regulators of cellular functions and disease processes.
Purpose of the Study:
- To review the current literature on microRNAs in pediatric otolaryngology.
- To discuss the potential of miRNAs as diagnostic biomarkers.
- To explore the therapeutic applications of miRNAs in pediatric ENT diseases.
Main Methods:
- Literature review of microRNA research relevant to pediatric otolaryngology.
- Analysis of miRNA function in cellular processes like proliferation, survival, and inflammation.
- Evaluation of miRNA stability and presence in various bodily fluids for biomarker potential.
Main Results:
- MicroRNAs are abnormally expressed in numerous diseases within pediatric otolaryngology.
- miRNAs are stable and detectable in tissues, blood, saliva, and urine, indicating biomarker utility.
- The direct gene modulation capability of miRNAs suggests significant therapeutic potential.
Conclusions:
- MicroRNAs represent a promising area for developing novel diagnostic and therapeutic strategies in pediatric otolaryngology.
- Further research into miRNA biomarkers and therapies could lead to reduced patient morbidity.
- miRNA-based approaches offer a new frontier for managing pediatric ear, nose, and throat conditions.
Related Concept Videos
01:22MicroRNAs
24.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.2K
01:22MicroRNAs
4.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.0K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
266
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
266
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
314
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
314
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
237
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
237
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
305
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
305